Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.49 |
| ▸ | PPARA | Q07869 | 16/20 | 0.49 |
| ▸ | PPARG | P37231 | 14/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.40 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679227 | 0.91 | PPARD (0.52) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4679304 | 0.87 | PPARA (0.43) | PPARDPPARAPPARG | |
| SCHEMBL4681928 | 0.86 | MAPT (0.42) | PPARDPPARAPPARGHDAC1 | |
| SCHEMBL4679104 | 0.83 | PPARG (0.43) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4679028 | 0.82 | PPARD (0.46) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4681897 | 0.81 | PPARD (0.46) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4681739 | 0.80 | PPARA (0.51) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4679444 | 0.79 | FBP1 (0.38) | PPARDPPARAPPARGHDAC3HDAC4 | |
| SCHEMBL4683027 | 0.79 | PPARA (0.45) | PPARDPPARAPPARG | |
| SCHEMBL6191959 | 0.78 | PPARD (0.41) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | claimed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | claimed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | claimed |
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | PPARD 223/4885PPARA 54/4885PPARG 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.